|Scientific Subdivisions | The Journal of Molecular Diagnostics
Contact AMP | Sign In | Join / Renew | Go To CHAMP
December 11, 2014: More than 1,900 attendees plus nearly as many exhibitors gathered for the AMP 2014 Annual Meeting. Highlights included an address by Francis Collins, a conversation with the FDA, and AMP's first ever Advocacy Day. Thanks to everyone who participated for making the meeting a success!
November 18, 2014: AMP joined the AMA and numerous other organizations in writing a letter to the FDA asking them to withdrawal the proposed draft guidance which seeks to regulate laboratory developed tests (LDTs). The letter urges the FDA to engage in the notice and comment rulemaking process as required under the Administrative Procedures Act (APA).
November 14, 2014: Uta Francke, MD was awarded the AMP Award for Excellence in Molecular Diagnostics; Aaron Bossler, MD, PhD received the AMP Meritorious Service Award, and Elaine Lyon, PhD, was presented with the Jeffrey A. Kant Leadership Award.
November 13, 2014: AMP President, Elaine Lyon, PhD, announced the formation of the Informatics Subdivision. The groundswell of interest by AMP members clearly identified the need for a subdivision of the Association dedicated to informatics. .
In this pre-Annual Meeing issue, check out highlights of the meeting as well as a snapshot of AMP's initiatives in the realms of education, advocacy, innovation & improved patient care.
October 23, 2014: The late-breaking session, titled, "Framework for Oversight of LDTs: A Conversation with FDA" is scheduled for Thursday, November 13, 2014 at 1:00pm EST. Immediately following, AMP will host a press conference, convening a panel of molecular pathology clinical professionals, from a variety of clinical laboratory settings, to appropriately frame the discussion regarding clinical care and appropriate regulation.
September 30, 2014: The Draft Guidance released today is almost identical to the Anticipated Details of the Draft Guidance of the Framework for Oversight of LDTs released on July 31. AMP continues to have deep concerns about the Framework itself and possible FDA regulation of laboratory developed procedures more generally. We look forward to conversations with the FDA during a special session at the AMP Annual Meeting next month.
September 2014: In a letter to the U.S. House of Representatives Committee on Energy and Commerce, Subcommittee on Health, AMP reaffirmed its position that an extensive new regulatory scheme such as that proposed by FDA poses an enormous threat to future diagnostic development, and to the health and well-being of patients.
September 2014: In a letter to CMS, AMP expressed concern over revisions to Part B Proposed Rule for CY 2015, focusing on five specific areas of importance to AMP members.
July/August 2014: AMP sent a letter and and co-signed a letter with 123 other organizations opposing S 1347. This legislation would place harmful restrictions on medical and scientific meetings that would threaten scientific progress and the ability of federal employee physicians to get essential continuing medical education.
July 2014: AMP urged the USPTO to make it clear that applications that attempt to claim the associations between genetic changes and physical characteristics or physiological effects, whether through process claims that in effect claim these natural relationships, or through claims on the gene sequences themselves, are directed toward patent ineligible subject matter.
July 2014: AMP reaffirms its position that the current CLIA program at the Centers for Medicare & Medicaid Services (CMS) provides appropriate oversight for LDTs.
The first-ever annual report includes membership statistics, milestone & achievements, and a financial review of the Association.
AMP Past President, Jennifer Hunt, MD, MEd, announced last week the newly elected leadership for AMP. We thank them for their upcoming service and thank all of you for voting!
June 2014: In a letter to Chairman Fred Upton and Representative Diana DeGette, AMP encouraged Congress to work to remove regulatory and reimbursement hurdles harming the diagnostic industry.
May 2014: In a letter to Dr. Jeffrey Shuren, AMP expressed concerns over FDA's inclusion of medical practice recommendations in product labeling for in vitro diagnostic tests.
April 2014: "We are incredibly honored to have Dr. Collins with us," said Elaine Lyon, MD, PhD, AMP President," he pioneered the field of genomics and continues to help create the landscape for precision medicine and the work of AMP members."
April 2014: Report in the May issue of JMD provides recommendations for both the baccalaureate and master's levels of education. "As the organization that is home to all molecular diagnostic professionals, AMP has a responsibility to help guide the training for future molecular technologists," said Elaine Lyon, PhD, AMP President.
April 2014: "We are pleased to join ASCP in recognizing the tremendous contributions of laboratory professionals whose specialized training and expertise are essential to the interpretation of test results, which enable patients and their physicians to make more informed treatment and care decisions," said AMP President Elaine Lyon, PhD.
Dr. Raymond R. Tubbs, a good friend and colleague of many AMP members, passed away early Saturday morning, April 19, 2014. Ray joined AMP in April 1995 and was a member of the Strategic Planning Committee. Continued..
March 2014: AMP outlines significant concerns regarding sweeping changes to the Clinical Laboratory Fee Schedule (CLFS) in SGR patch legislation, submits letter to House Majority Leader.